Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.

Soave DF, Oliveira da Costa JP, da Silveira GG, Ianez RC, de Oliveira LR, Louren├žo SV, Ribeiro-Silva A.

Diagn Pathol. 2013 Feb 18;8:29. doi: 10.1186/1746-1596-8-29.

2.

Differential expression of HIF-1╬▒ in CD44+CD24-/low breast ductal carcinomas.

Oliveira-Costa JP, Zanetti JS, Silveira GG, Soave DF, Oliveira LR, Zorgetto VA, Soares FA, Zucoloto S, Ribeiro-Silva A.

Diagn Pathol. 2011 Aug 8;6:73. doi: 10.1186/1746-1596-6-73.

3.

Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.

Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA, Brentani MM.

Oncol Rep. 2012 Jan;27(1):28-38. doi: 10.3892/or.2011.1477. Epub 2011 Sep 28.

PMID:
21956537
4.

CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.

Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ, Ha SW.

World J Gastroenterol. 2013 Mar 7;19(9):1438-43. doi: 10.3748/wjg.v19.i9.1438.

5.

CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.

Li Z, Chen K, Jiang P, Zhang X, Li X, Li Z.

Diagn Pathol. 2014 Apr 8;9:79. doi: 10.1186/1746-1596-9-79.

6.

[Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].

Wang A, Lu L, Wang Y, Sun Y, Zhang Y, Guo C, Gu Y, Liu A.

Zhonghua Bing Li Xue Za Zhi. 2014 Jan;43(1):20-4. Chinese.

PMID:
24713244
7.

CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis.

Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW, Lee CC.

BMC Gastroenterol. 2012 Jul 28;12:95. doi: 10.1186/1471-230X-12-95.

8.

Management and outcome of patients with malignant salivary gland tumors.

Bell RB, Dierks EJ, Homer L, Potter BE.

J Oral Maxillofac Surg. 2005 Jul;63(7):917-28.

PMID:
16003616
9.

Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.

Augustin F, Fiegl M, Schmid T, Pomme G, Sterlacci W, Tzankov A.

J Clin Pathol. 2015 May;68(5):368-73. doi: 10.1136/jclinpath-2014-202819. Epub 2015 Mar 2. Erratum in: J Clin Pathol. 2015 May;68(5):doi:10.1136/jclinpath-2014-202819corr1.

PMID:
25731190
10.

Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor.

Allard MA, Bachet JB, Beauchet A, Julie C, Malafosse R, Penna C, Nordlinger B, Emile JF.

Diagn Pathol. 2012 Nov 13;7:156. doi: 10.1186/1746-1596-7-156.

11.

CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.

Lin Y, Zhong Y, Guan H, Zhang X, Sun Q.

J Exp Clin Cancer Res. 2012 Jul 4;31:59. doi: 10.1186/1756-9966-31-59.

12.

Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.

Liu C, Luo Y, Liu X, Lu P, Zhao Z.

Cancer Biother Radiopharm. 2012 Jun;27(5):324-8. doi: 10.1089/cbr.2011.1155.

PMID:
22702496
13.

The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.

Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L.

Hum Pathol. 2008 Jul;39(7):1096-102. doi: 10.1016/j.humpath.2007.12.003. Epub 2008 May 20.

PMID:
18495204
14.

CD44+/CD24- cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast.

Tiezzi DG, Valejo FA, Marana HR, Carrara HH, Benevides L, Antonio HM, Sicchieri RD, Milanezi CM, Silva JS, de Andrade JM.

Med Oncol. 2012 Sep;29(3):1479-85. doi: 10.1007/s12032-011-0014-x. Epub 2011 Jun 29.

PMID:
21713550
15.

Gastric micropapillary carcinoma: A distinct subtype with a significantly worse prognosis in TNM stages I and II.

Eom DW, Kang GH, Han SH, Cheon GJ, Han KH, Oh HS, Kim JH, Jang HJ, Hong SM.

Am J Surg Pathol. 2011 Jan;35(1):84-91. doi: 10.1097/PAS.0b013e3181ff61e2.

PMID:
21164291
16.

CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.

Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS, Cha BH.

Pancreas. 2014 Apr;43(3):380-8. doi: 10.1097/MPA.0000000000000097.

PMID:
24622067
17.

In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.

Perrone G, Gaeta LM, Zagami M, Nasorri F, Coppola R, Borzomati D, Bartolozzi F, Altomare V, Trodella L, Tonini G, Santini D, Cavani A, Muda AO.

PLoS One. 2012;7(9):e43110. doi: 10.1371/journal.pone.0043110. Epub 2012 Sep 13.

18.

Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.

Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M.

Cancer Sci. 2011 Dec;102(12):2132-8. doi: 10.1111/j.1349-7006.2011.02063.x. Epub 2011 Sep 14.

19.

Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.

Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H.

Diagn Pathol. 2012 Sep 24;7:127. doi: 10.1186/1746-1596-7-127.

20.

[Expression and significance of CD44(+)ESA(+)CD24(-/low), stem cell markers for breast cancer, in non-small-cell lung carcinoma].

Lu ZQ, Li HG, Zhang HZ, Fan MJ, Shen XM, He XX.

Ai Zheng. 2008 Jun;27(6):575-9. Chinese.

PMID:
18570728
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk